Get started

Urovant Sciences GmbH (Switzerland)

Homepage: urovant.com
Alternate names: Urovant Sciences, Urovant Sciences GmbH, Urovant Sciences LLC
ROR: 02sdbec13
OpenAlex ID: I4405267442
International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR
2020 · David Staskin, Jeffrey Frankel, et al. · The Journal of Urology · 135
Increased risk of incident dementia following use of anticholinergic agents: A systematic literature review and meta‐analysis
2020 · Roger R. Dmochowski, Sydney Thai, et al. · Neurourology and Urodynamics · 125
PDF
Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR)
2020 · David Staskin, Jeffrey Frankel, et al. · The Journal of Urology · 50
Selectivity and Maximum Response of Vibegron and Mirabegron for β3-Adrenergic Receptors
2022 · Benjamin M. Brucker, Jennifer King, et al. · Current Therapeutic Research · 42
PDF
Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study
2021 · Susann Varano, David Staskin, et al. · Drugs & Aging · 31
PDF
Vibegron improves quality‐of‐life measures in patients with overactive bladder: Patient‐reported outcomes from the EMPOWUR study
2020 · Jeffrey Frankel, Susann Varano, et al. · International Journal of Clinical Practice · 22
PDF
Comparative analysis of real‐world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims study
2024 · Benjamin Chastek, Adam Carrera, et al. · Neurourology and Urodynamics · 17
Pharmacokinetics and Safety of Vibegron 75 mg Administered as an Intact or Crushed Tablet in Healthy Adults
2022 · Jennifer King, Ann Walker, et al. · Clinical Pharmacology in Drug Development · 17
PDF
Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial
2021 · Michael A. Weber, Cornelia Haag-Molkenteller, et al. · Blood Pressure Monitoring · 16
Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA
2022 · Jing Voon Chen, James C. Gahn, et al. · PharmacoEconomics · 13
PDF
Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial.
2022 · Michael A Weber, Cornelia Haag-Molkenteller, et al. · PubMed Central · 11
PDF
Efficacy and Safety of Vibegron for the Treatment of Overactive Bladder in Women: A Subgroup Analysis From the Double-Blind, Randomized, Controlled EMPOWUR Trial
2022 · Diane K. Newman, Elizabeth Thomas, et al. · Urogynecology · 8
CYP2D6 Substrate Dispensing Among Patients Dispensed Mirabegron: An Administrative Claims Analysis
2022 · Mary E. Ritchey, Jingjun Wang, et al. · Drugs - Real World Outcomes · 6
PDF
A Plain Language Summary on the Effect of the Medication Vibegron on Blood Pressure and Heart Rate in People with Overactive Bladder
2023 · Michael A Weber, Alvaro Lucioni, et al. · Future Cardiology · 3
Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double‐blind , placebo‐controlled phase 2 trial
2022 · Brian E. Lacy, Jennifer King, et al. · Neurogastroenterology & Motility · 3
PDF
3-month Interim Results of a Phase 4, Real-world Study (composur) to Evaluate Vibegron in Patients With Overactive Bladder
2023 · S MacDiarmid, R Dmochowski, et al. · Continence · 1
Assessment of Codispensing Patterns of Mirabegron and Prespecified CYP2D6 Substrates in Patients with Overactive Bladder
2023 · Jingjun Wang, Mary E. Ritchey, et al. · Drugs - Real World Outcomes · 1
PDF
6 Efficacy and Safety of a Novel Gene Therapy (uro-902; Pvax/hslo) in Female Patients With Overactive Bladder Syndrome and Urgency Urinary Incontinence: Results From a Phase 2a Trial
2022 · K Peters, E Enemchukwu, et al. · Continence · 1
PDF
Efficacy of Vibegron on Urgency Urinary Incontinence and Patient-reported Quality of Life: Subgroup Analysis From the Empowur Trial
2023 · D Staskin, J Frankel, et al. · Continence
297 Long-term Efficacy and Safety of Vibegron for Overactive Bladder Syndrome in Patients ≥65 Years Old: Analysis From the Empowur Extension Trial
2022 · D Staskin, J Frankel, et al. · Continence
PDF
Reply by Authors
2021 · David Staskin, Jeffrey Frankel, et al. · The Journal of Urology
Reply by Authors
2020 · David Staskin, Jeffrey Frankel, et al. · The Journal of Urology
Works count: 22
Citation count: 1,127
Year
Topic
Type